Regeneron Pharmaceuticals, Inc.
General ticker "REGN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $67.3B (TTM average)
Regeneron Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 40.1%.
Estimated limits based on current volatility of 1.5%: low 595.58$, high 616.83$
Factors to consider:
- Company included in S&P500 list
- Company included in NASDAQ-100 index
- Company pays dividends (quarterly): last record date 2026-05-20, amount 0.94$ (Y0.61%)
- Total employees count: 15410 (+2.0%) as of 2025
- US accounted for 8.5% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Dependence on key products, Reimbursement risks, Regulatory and compliance, Supply chain disruptions, Labor/talent shortage/retention
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [581.48$, 836.90$]
- 2026-12-31 to 2027-12-31 estimated range: [642.33$, 905.12$]
Financial Metrics affecting the REGN estimates:
- Negative: with PPE of 17.4 at the end of fiscal year the price was high
- Positive: Operating profit margin, % of 24.93 > 18.39
- Positive: Inventory ratio change, % of 0.77 <= 0.78
- Positive: Return on assets ratio (scaled to [-100,100]) of 10 > 6.06
- Negative: Investing cash flow per share per price, % of -0.78 <= -0.60
- Positive: Shareholder equity ratio, % of 77.07 > 64.29
- Negative: negative Industry operating income (median)
Short-term REGN quotes
Relationship graph
Long-term REGN plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $13,119.30MM | $14,148.60MM | $14,352.90MM |
| Operating Expenses | $9,072.20MM | $10,157.90MM | $10,775.00MM |
| Operating Income | $4,047.10MM | $3,990.70MM | $3,577.90MM |
| Non-Operating Income | $152.20MM | $789.20MM | $1,652.80MM |
| Interest Expense | $73.00MM | $55.20MM | $43.80MM |
| R&D Expense | $4,625.10MM | $5,233.00MM | $5,974.30MM |
| Income(Loss) | $4,199.30MM | $4,779.90MM | $5,230.70MM |
| Taxes | $245.70MM | $367.30MM | $725.80MM |
| Net Income(Loss)* | $3,953.60MM | $4,412.60MM | $4,504.90MM |
| Stockholders Equity | $25,973.10MM | $29,353.60MM | $31,256.90MM |
| Inventory | $2,580.50MM | $3,087.30MM | $3,200.80MM |
| Assets | $33,080.20MM | $37,759.40MM | $40,558.70MM |
| Operating Cash Flow | $4,594.00MM | $4,420.50MM | $4,978.90MM |
| Capital expenditure | $926.40MM | $755.90MM | $898.40MM |
| Investing Cash Flow | $-3,185.10MM | $-2,468.10MM | $-629.10MM |
| Financing Cash Flow | $-1,790.10MM | $-2,200.50MM | $-3,715.40MM |
| Earnings Per Share** | $37.05 | $40.90 | $43.07 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.